Long‐term Hypotensive Effect of Atenolol (ICI 66.082), a New β‐adrenergic Blocking Agent
Authors:
- 12 January 1976
- journal article
- research article
- Published by Wiley in Acta Medica Scandinavica
- Vol. 199 (1-6) , 257-262
Abstract
A report is given from an on‐going multicenter trial in Sweden, in which 117 hypertensive patients have been treated with a new cardioselective β‐adrenergic blocking agent, atenolol (ICI 66.082, Tenormin®) for an average of six months (range 2–21). Statistically significant reductions of BP were observed, recumbent by 29/19 mmHg (p < 0.0001) and standing by 28/18 mmHg (p < 0.0001). Few and comparatively mild sideeffects were seen.Keywords
This publication has 12 references indexed in Scilit:
- Letter: Skin reactions to beta-blockers.BMJ, 1974
- Letter: Skin reactions to practolol.BMJ, 1974
- Management of severe hypertensionThe American Journal of Cardiology, 1973
- INITIAL CLINICAL EXPERIENCE WITH I.C.I. 66.082, A NEW β‐ADRENERGIC BLOCKING AGENT, IN HYPERTENSION.Acta Medica Scandinavica, 1973
- Propranolol in hypertension: A study of long-term therapy, 1964–1970American Heart Journal, 1972
- Propranolol therapy in essential hypertensionAmerican Heart Journal, 1972
- Propranolol in hypertensionJournal of Molecular Medicine, 1972
- Treatment of Hypertension with PropranololBMJ, 1969
- EFFECT OF PROPRANOLOL IN MILD HYPERTENSIONThe Lancet, 1966
- Use of Propranolol (Inderal) in Treatment of HypertensionBMJ, 1964